Entering text into the input field will update the search result below

Avalon GloboCare (NASDAQ:AVCO) Expands Co-Development Program With MIT To Combat Cancer Metastasis

Mar. 22, 2021 9:26 AM ETALBT
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Seeking Alpha Analyst Since 2014

Robert E. Kreh - Principal - Small Cap Solutions, LLC

Business Development-Marketing Consultation-IR

Over 30 years Of Management-Sales-Corporate Finance & IR

Connection for Sources of Pubco & Private Company

Funding Financing & Debt Restructure


  • Dual cutting edge technology approach using CRISPR-based genome editing and QTY code-based truncated chemokine receptors.
  • Expansion of co-development program with Dr. Shuguang Zhang at the Massachusetts Institute of Technology (MIT) Media Lab to halt mobilization and spread of cancer.
  • Cellular Medicine - Cell Tech Bio Developer.
  • Cellular Immunotherapy.

FREEHOLD, N.J., March XX, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announces the expansion of its co-development research program with the Massachusetts Institute of Technology (MIT) to apply two leading technologies—CRISPR-based genome editing and QTY protein design—to potentially treat and prevent cancer metastasis.

Metastasis—the spreading of cancer cells from the initial tumor site to surrounding tissues and distant organs—is responsible for the vast majority of cancer deaths. In an ongoing co-development research program, Avalon and the laboratory of Dr. Shuguang Zhang at MIT’s Media Lab, have developed a novel approach to potentially block the signals that cancer cells require to metastasize in order to prevent cancer spread and death.

Cancer cells mobilize and travel to other organs using the chemokine signaling network, made up of chemokine receptors on the surface of healthy cells and soluble ligands that bind these receptors. Dr. Zhang’s MIT laboratory is applying their novel QTY protein code technology to design truncated versions of receptors that can act as decoys, attracting cancer cells and preventing them from spreading to other organs. Avalon and MIT researchers are also working on a second approach—combining the QTY technology with the CRISPR-Cas9 gene editing system to re-program cell types that typically stimulate nearby cancer cells to spread, thereby deterring cancer metastasis.

Avalon and MIT’s collaboration on the QTY code has already successfully generated a prototype device to soak up the excess chemokines and cytokines produced in the body that lead to a potentially fatal ‘cytokine storm,’ which can occur in patients with COVID-19 and in cancer patients being treated with CAR T-cell therapy.

“I am delighted to expand this fruitful and important collaboration with Avalon with the goal of advancing our ability to treat and prevent cancer metastasis,” said Dr. Shuguang Zhang, Head of the Laboratory of Molecular Architecture at MIT’s Media Lab. “We have a talented team at MIT, including the enthusiastic support of MIT and Harvard’s Broad Institute professor, Dr. Feng Zhang, a pioneer and expert of CRISPR-based genomic editing in mammalian cells. Through our collaboration, we have been able to develop

cutting edge technology that we believe has the potential to prevent the spread of cancer to other tissues, which ultimately leads to death.”

“This new endeavor builds on our collaboration with MIT using the QTY code technology to develop innovative therapies for cancer metastasis,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. “We are working diligently and remain dedicated to finding innovative ways of combatting cancer metastasis with the health of patients at the forefront of our minds.”

About Avalon GloboCare Corp.

Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.

For the latest updates on Avalon GloboCare's developments, please follow our twitter at @avalongc_avco

Avalon Globocare

Avalon GloboCare Corp. (AVCO) Stock Price, News, Quote & History - Yahoo Finance

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (SEC.gov | HOME). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

Contact Information:

Avalon GloboCare Corp.

4400 Route 9, Suite 3100

Freehold, NJ 07728


Investor Relations:

Crescendo Communications, LLC

Tel: (212) 671-1020 Ext. 304


No alt text provided for this image

Disclaimer: All Micro/Small Cap Company(ies) profile(S) are/have been compiled by Small Cap Solutions, LLC based on information believed to be true and gathered either from client companies and/or third party(‘s)/web sites. These profiles are not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and has been prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the statements either expressed or implied herein.

Prospective investors are advised to review the Company’s periodic filings with the Securities and Exchange Commission www.sec.gov - yahoofinance.com or at otcmarkets.com Small Cap Solutions, LLC may receive cash or stock from a third party for investor relations services rendered.

Small Cap Solutions, LLC and/or its Principal/Employees are not registered Broker(S)/Broker Dealer(S) with FINRA or the SEC. Small Cap Solutions, LLC does not make any buy/sell recommendations at any time, but may state their opinion on companies, etc. That is not meant to be a recommendation. All information disseminated by Small Cap Solutions, LLC is believed to be true and public.

Small Cap Solutions, LLC is compensated in cash by Client Companies and/or Third Parties for Marketing Consultation & Investor Relations.

Additional inquiries available by email to robkreh@smallcapsolutions.com or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message.

I/We do Not own any stock/shares of any company that is currently under contract. I/We have No intention of purchasing any stock/shares in any company currently under contract. I/We feel this eliminates any appearance of conflict of interest.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Analyst's Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.